Cariprazine: Patients with Treatment-Resistant Schizophrenia

Código QR

Cariprazine: Patients with Treatment-Resistant Schizophrenia

Thomas Aubel Kliniken Essen-Mitte, Klinik für Psychiatrie, Psychotherapie, Psychosomatik und Suchtmedizin, Essen, GermanyCorrespondence: Thomas AubelKliniken Essen-Mitte, Klinik für Psychiatrie, Psychotherapie, Psychosomatik und Suchtmedizin, Henricistraße 92, Essen, 45136, GermanyTel +4920117430005...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Aubel T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	cariprazine schizophrenia paranoid schizophrenia negative symptoms resistant schizophrenia antipsychotics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/9b21135d1adb403f8c109d0cc7935cca
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
por: Montes JM, et al.
Publicado: (2021)

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Octavian Vasiliu
Publicado: (2021)

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
por: Aleksandr M. Reznik, et al.
Publicado: (2020)

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Citrome L
Publicado: (2018)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy Á, et al.
Publicado: (2021)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
por: Barabássy Á, et al.
Publicado: (2021)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
por: Correll CU, et al.
Publicado: (2019)

Update on schizophrenia and bipolar disorder: focus on cariprazine
por: Roberts RJ, et al.
Publicado: (2016)

The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2021)

Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study
por: Liang Y, et al.
Publicado: (2017)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
por: Zhang LL, et al.
Publicado: (2016)

Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
por: Müller HHO, et al.
Publicado: (2021)

Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
por: Correll CU, et al.
Publicado: (2020)

Lack of tolerable treatment options for patients with schizophrenia
por: Citrome L, et al.
Publicado: (2015)

Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
por: Moga S, et al.
Publicado: (2021)

Influence of CFH gene on symptom severity of schizophrenia
por: Zhang C, et al.
Publicado: (2017)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen Y, et al.
Publicado: (2019)

Comparison of beta-endorphin and CGRP levels before and after treatment for severe schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2016)

Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study
por: Huang YC, et al.
Publicado: (2018)

Relationship between social and cognitive functions in people with schizophrenia
por: Tominaga T, et al.
Publicado: (2018)

Psychopharmacotherapy of Suicidal Behavior in Schizophrenia and Schizophrenic Spectrum Disorders
por: L. A. Ivanova
Publicado: (2020)

Pilot Validation Study of the Japanese Translation of the Brief Negative Symptoms Scale (BNSS)
por: Hashimoto N, et al.
Publicado: (2019)

Validation of the Chinese Version of the 16-Item Negative Symptom Assessment
por: Huang B, et al.
Publicado: (2020)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
por: Emsley R, et al.
Publicado: (2018)

Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile
por: de Filippis R, et al.
Publicado: (2021)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi T, et al.
Publicado: (2017)

Severe arrhythmia induced by orally disintegrating aripiprazole tablets (Bosiqing®): a case report
por: Shao Q, et al.
Publicado: (2015)

Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
por: Xu H, et al.
Publicado: (2019)

Irreversible Primary Visual Cortex Impairment in a Mouse Model of High-Risk Schizophrenia
por: Chen X, et al.
Publicado: (2021)

Validation of the Dutch Version of the Brief Negative Symptom Scale
por: Seelen-de Lang BL, et al.
Publicado: (2020)

Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
por: Iyo M, et al.
Publicado: (2021)

Cognitive dysfunction and negative symptoms in patients with schizophrenia and their first-degree relatives from simplex and multiplex families
por: Zhang Z, et al.
Publicado: (2018)

Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole
por: Peters-Strickland T, et al.
Publicado: (2016)

Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
por: Faden J, et al.
Publicado: (2019)

Drug Attitude, Insight, and Patient’s Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey
por: Nagai N, et al.
Publicado: (2020)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
por: Emsley R, et al.
Publicado: (2017)

Increased Plasma Kynurenic Acid Levels are Associated with Impaired Attention/Vigilance and Social Cognition in Patients with Schizophrenia
por: Huang X, et al.
Publicado: (2020)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni C, et al.
Publicado: (2016)

Serum C-Reactive Protein in Patients with Deficit Schizophrenia and the Relationship with Cognitive Function
por: Pan LH, et al.
Publicado: (2020)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2019)